Brain-derived phosphorylated TAU217

There is 1 paper on brain-derived phosphorylated TAU217 in aging research: 1 observational study in people.

Biomarker

1 paper studies it2 findings

1 new paper in 30 daysSee all 1 papers on brain-derived phosphorylated TAU217

“BD‐pTau217 and total pTau217 had similar discrimination (full‐follow‐up AUC = 0.66 each; high‐versus‐low hazard ratios [HRs]; 95% confidence interval [CIs]: 2.8 [1.89–4.06] and 2.9 [1.96–4.35], respectively).”
Prognostic value of plasma brain‐derived phosphorylated TauAlzheimer's & dementia : the journal of the Alzheimer's Association2026doi:10.1002/alz.71983
  • Humans1

Associations

2

Progression to amyloid PET positivity

upin humans1HR 10.54

1 study
  1. Brain-derived phosphorylated TAU217 predicts progression to amyloid PET positivity in humans (Initially amyloid-negative participants) (2.5 years: HR 10.54 (95% CI 2.3–48.1), tdAUC 0.82 versus 0.69; 4 years: HR 7.03 (95% CI 1.9–25.6), tdAUC 0.77 versus 0.64).

    HumansInitially amyloid-negative participantsplasma2.5 and 4 years

More on Progression to amyloid PET positivity

Progression to mild cognitive impairment or Alzheimer's disease dementia

upin humans1HR 2.8

1 study
  1. Brain-derived phosphorylated TAU217 predicts progression to mild cognitive impairment or Alzheimer's disease dementia in humans (Cognitively unimpaired participants; high versus low baseline biomarker) (HR 2.8, 95% CI 1.89–4.06; AUC 0.66).

    HumansCognitively unimpaired participants; high versus low baseline biomarkerplasmaMedian follow-up of 6 yearsn = 508

More on Progression to mild cognitive impairment or Alzheimer's disease dementia

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months